17th Annual World Congress Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC) is organized by The Metabolic Institute of America (TMIOA) and will be held from Dec 04 - 07, 2019 at Hilton Los Angeles/Universal City, Los Angeles, California, United States of America. This CME Conference has been approved for a maximum of 27.00 AMA PRA Category 1 Credits.
This educational initiative is designed for cardiologists, endocrinologists, gastroenterologists, oncologists, internists, diabetologists, OBGYNs, pediatricians, dietitians, nurse practitioners, pharmacists, and any other health care professionals who are interested in insulin resistance, diabetes, obesity, cardiovascular disease, and multiple metabolic mechanisms’ effects on health and society, as well as on potential treatment and prevention.
This Conference is a unique and exciting multidisciplinary program. The Congress is the premiere global meeting dedicated to diabetes, obesity, lipids, cardiovascular disease (CVD), and energy balance, linking basic research to clinical practice, and highlighting our theme: Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.
For more than a decade, the WCIRDC has brought researchers, physicians and healthcare professionals together for a distinctive international program that bridges the latest developments from the bench to bedside. “I heard it first at the Congress” is a frequent remark from the audience over the years, many of whom attend year after year. Researchers present their latest data on everything from biomarkers to new physiologic insights to new ideas for therapies. WCIRDC offers attendees a unique experience to interact with the distinguished global faculty for a collaborative experience that explores the newest understanding of metabolic diseases and the development of future therapeutic modalities.
Since Dr. Gerald Reaven’s pioneering work crystallized the relationship between insulin resistance (IR), diabetes, and CVD, the Congress’ focus has expanded to the fat cell, lipids, the kidney, the brain, bone, energy metabolism, inflammation, CVD complications and cancer. The Congress addresses atherosclerosis, hypertension, and hypercoagulation as well as pharmaceutical interventions like incretins, SGLT2i’s and PCSK9i’s to name a few. The goal is to understand the state of the art pathophysiology and to develop appropriate comprehensive clinical management strategies.
For primary care clinicians, the Congress will feature a series of workshops and “meet the expert” panels addressing the clinical management of kidney disease, diabetes, obesity, lipids, the high risk CVD patients and more. To make basic and clinical research topics relevant to clinical medicine, there will be commentaries on its clinical implications by recognized clinical experts. The Congress’ intimate setting promotes a lot of personal contact between participants and the faculty wherein everyone learns from the free flow of questions and personal observations.
The Congress attracts state-of-the-art abstracts from around the globe. These abstracts will be published in Endocrine Practice (ISSN: 1530-891X), a peer-reviewed journal published twelve times a year, is the official journal of the American Association of Clinical Endocrinologists (AACE).
Typically, articles about the meeting are published in several medical journals, such as Endocrine Practice, Metabolism, The Journal of Diabetes, and Diabetes Care.
The program is designed to evaluate both the clinical and basic science aspects of diabetes, obesity, dyslipidemia and CVD, by focusing on insulin resistance, hyperinsulinemia, fat cells, the heart, the kidneys, and energy metabolism. The goal is to understand its pathophysiology, and to develop appropriate comprehensive clinical management plans.
Upon completion of this meeting, participants should be able to:
• Provide comprehensive management of diabetes, by addressing obesity, hypertension, dyslipidemia, and cardiovascular risks.
• Discuss the role of obesity in the development of cardiometabolic conditions
• Discuss the role of incretins in the management of obesity, diabetes, and prevention of CVD
• Be aware of the results of cardiovascular outcome trials and understand the potential role of SGLT2i & GLP1ra in managing Diabetes and CVD
• Evaluate the extent of macrovascular and microvascular disease in diabetes and obesity
• Address the risks of heart disease in patients with diabetes
• Explain the role of lipids, in particular low-density lipoprotien (LDL-C) and non- HDL-C, in the development of atherosclerosis
• Examine the role of PCSK9 and the newly developed monoclonal antibodies- the PCSK9 inhibitors in LDL homeostasis and on the contemporary approaches to management and prevention of CVD
• Describe contemporary approaches to congestive heart failure
• Explain the relationship of the kidney to insulin resistance, diabetes and CVD
• Explain the pathophysiology and complications of fatty liver disease and its relationship to diabetes and CVD
• Discuss the role of SGLT2i in the management of diabetes its potential role beyond glycemia and known complications.
• Evaluate bariatric surgery and newly-developed procedures, as well as devices and their effect on weight loss and hormones, and their long-term outcomes
|Contact No. :||1-818-342-1889
November 11, 2019
|Registration Type||Last Date||Price|
|General Attendee - Late fee||30 Nov,2019||USD 650.00|
|Fellow/Resident - Late fee||30 Nov,2019||USD 400.00|
|Students - Late fee||30 Nov,2019||USD 175.00|
|Single day Tickets - Staurday fee||30 Nov,2019||USD 250.00|
|Registration Type||End Date||Price|
|General Attendee - Early fee||30 Aug,2019||USD 495.00|
|General Attendee - Regular fee||01 Nov,2019||USD 550.00|
|Fellow/Resident - Early fee||30 Aug,2019||USD 295.00|
|Fellow/Resident - Regular fee||01 Nov,2019||USD 350.00|
|Students - Early fee||30 Aug,2019||USD 175.00|
|Students - Regular fee||01 Nov,2019||USD 175.00|
|Single day Tickets - Thursday fee||30 Aug,2019||USD 250.00|
|Single day Tickets - Friday fee||01 Nov,2019||USD 250.00|
Hilton Los Angeles/Universal City
555 Universal Hollywood Dr, Universal City
Los Angeles, California, United States of America
Hilton Los Angeles/Universal City,
555 Universal Hollywood Dr, Universal City,
Los Angeles, California, United States of America 91608,